Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Intellia Therapeutics (NTLA) Stock Price & Analysis
2,749 Followers
NTLA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.37 - $46.00
Previous Close$25.79
Volume1.48M
Average Volume (3M)1.62M
Market Cap
$2.49B
Enterprise Value$1.81B
Total Cash (Recent Filing)$791.29M
Total Debt (Recent Filing)$110.86M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Aug 01, 2024EPS Estimate
-$1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.37
Shares Outstanding96,475,421
10 Day Avg. Volume1,564,937
30 Day Avg. Volume1,624,718
Standard Deviation0.24
R-Squared0.16
Alpha0.00832
Financial Highlights & Ratios
Price to Book (P/B)2.23
Price to Sales (P/S)80.75
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue34.36
Enterprise Value/Gross Profit49.83
Enterprise Value/Ebitda-7.48
Forecast
1Y Price Target
$59.73Price Target Upside129.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Intellia Therapeutics News
PremiumCompany Announcements
Intellia Therapeutics Welcomes New CFO, Announces Executive Transition
PremiumPress Releases
Intellia Therapeutics Announces CFO Transition
Bulls Say, Bears Say
Bulls Say
Clinical DataNTLA announced positive clinical data showing the ability to redose the CRISPR-LNP platform for the treatment of ATTR amyloidosis.
Gene EditingNTLA-2001 data demonstrate for the first time that gene editing can be safely redosed in humans, achieving the desired editing/effect.
Safety ProfileThe safety profile of the patients who were redosed is consistent with a single-dose treatment.
Bears Say
Competitive PositioningThe competitive positioning of the NTLA-2001 program as a fast-follower with what is expected to be a similar clinical profile puts Intellia in a tough position in the medium/long-term.
Financial PerformanceCollaboration revenues of $29mn (-129% y/y) were driven by a $21mn non-cash revenue adjustment related to the AvenCell collaboration.
Patient EnrollmentThe near-term commercial availability of vutrisiran is likely to adversely impact Intellia's ability to enroll patients in the MAGNITUDE pivotal study of NTLA-2001.
---
Ownership Overview
18.91% Insiders
26.52% Mutual Funds
29.83% Other Institutional Investors
24.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $19.37 and its highest was $46.00 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Currently, no data Available
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 13 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on May 09, 2024. The company reported -$1.12 earnings per share for the quarter, beating the consensus estimate of -$1.366 by $0.246.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -$1.22.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 96,475,420 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.12 in its last earnings report, beating expectations of -$1.366. Following the earnings report the stock price went up 8.087%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 302M.
---
Intellia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.73 (129.64% Upside)
$59.73 (129.64% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 421.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.65%
12-Months-Change
Fundamentals
Return on Equity
-43.60%
Trailing 12-Months
Asset Growth
-11.16%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
NTLA Earnings Call
Q1 2024
0:00 / 0:00
---
NTLA Revenue Breakdown
100.00% Collaboration revenue
---
NTLA Stock 12 Month Forecast
Average Price Target
$59.73
▲(129.64% Upside)
Technical Analysis
Best Analysts Covering NTLA
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
-7.09%
reiterated a buy rating 2 months ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of -7.09% per trade.
---